Outcome of chronic lymphocytic leukemia patients who switched from either ibrutinib or idelalisib to alternate kinase inhibitor: A retrospective study of the French innovative leukemia organization (FILO)

Wiley, American Journal of Hematology, 2(93), p. E52-E54, 2017

Journal article published in 2017 by Sophie Godet, Caroline Protin, Jehan Dupuis, Caroline Dartigeas, Jean-Noël Bastie, Charles Herbaux, Véronique Leblond, Sophie de Guibert, David Ghez, Annie Brion, Loïc Ysebaert

This paper is made freely available by the publisher.

Full text: Download

Preprint: archiving allowed

Upload

Postprint: archiving restricted

Upload

Published version: archiving forbidden

Policy details

Data provided by